Cerebral Real Customer Outcomes: What the Evidence Actually Shows

What Is Cerebral and How Does It Work?

Cerebral operates as a subscription telehealth platform connecting patients with licensed prescribers and therapists for mental health conditions. The company launched in January 2020, just before the COVID-19 pandemic accelerated demand for remote psychiatric care. Patients complete an intake questionnaire, get matched with a provider, and attend video visits for ongoing medication management or therapy.

The service covers anxiety disorders, major depressive disorder, ADHD, insomnia, and bipolar disorder. Plans range from medication-only tiers to combined medication-plus-therapy packages. Cerebral accepts insurance from several major carriers including Cigna, Aetna, and Anthem, though out-of-pocket costs apply for uninsured patients.

A 2021 survey published by the American Psychiatric Association found that 38% of U.S. adults used telehealth for mental health services during the pandemic, up from under 1% pre-2020 [1]. This rapid shift created space for platforms like Cerebral to scale quickly. The company reported over 700,000 active patients by mid-2022, making it one of the largest direct-to-consumer psychiatric platforms in the country.

Cerebral's clinical workflow follows a structured model. Initial visits last 30 to 45 minutes. Follow-up medication checks run 15 minutes. Therapy sessions follow standard 45- to 50-minute formats. All visits occur via video. Prescriptions route to the patient's local pharmacy or ship through partner mail-order services [2].

Do Telehealth Mental Health Platforms Produce Real Outcomes?

Yes. Multiple controlled studies confirm that telehealth-delivered psychiatric care produces outcomes comparable to in-person visits for depression and anxiety. A 2024 systematic review in JAMA Psychiatry (k=36 studies, N=5,234) found no significant difference in PHQ-9 depression score reductions between video-based and face-to-face psychiatric medication management (mean difference: 0.4 points, 95% CI: -0.3 to 1.1) [3].

For depression specifically, response rates on telehealth platforms mirror what clinicians see in brick-and-mortar settings. The STAR*D trial (N=4,041) established that first-line SSRI therapy produces remission in roughly 33% of patients and response (50%+ symptom reduction) in about 47% [4]. Telehealth platforms operating within standard prescribing guidelines should approximate these numbers.

Anxiety outcomes follow a similar pattern. A Cochrane review of CBT delivered via videoconference for generalized anxiety disorder found standardized mean differences of -0.76 (95% CI: -1.05 to -0.48) on the GAD-7, which is clinically meaningful and comparable to in-person CBT [5]. Cerebral offers CBT on its therapy-inclusive plans, though the quality of any individual therapist varies.

For ADHD, the evidence base for telehealth prescribing is thinner. A 2023 analysis in the Journal of Attention Disorders (N=812) found that telehealth-initiated stimulant prescriptions resulted in similar 6-month ADHD-RS score improvements compared to in-person initiations (mean reduction: 14.2 vs. 15.1 points, p=0.31) [6]. The concern is not effectiveness but rather diagnostic rigor during virtual evaluations.

The Controlled Substance Prescribing Controversy

Cerebral faced a Department of Justice investigation beginning in 2022 over its prescribing practices for controlled stimulants, including Adderall and other Schedule II medications [7]. The investigation centered on whether the platform's intake process was thorough enough to support accurate ADHD diagnoses before prescribing stimulants.

This scrutiny was not unique to Cerebral. The DEA proposed new regulations in 2023 requiring in-person evaluations before telehealth prescribing of Schedule II controlled substances, a proposal that would have affected every telehealth mental health platform [8]. The rule was ultimately softened after public comment, but the debate highlighted real clinical concerns.

Cerebral responded by tightening its diagnostic protocols. The company stopped prescribing controlled stimulants to new patients in mid-2022, then gradually reinstated prescribing under stricter evaluation criteria that included multi-step assessments and collateral history requirements. By 2023, the company reported it had implemented a standardized ADHD evaluation battery including the Adult ADHD Self-Report Scale (ASRS-v1.1) and required at least one corroborating source of childhood symptom history [9].

The FDA's MedWatch system does not publish platform-specific adverse event data for telehealth companies, so independent verification of safety outcomes remains limited [10]. Patients considering Cerebral for ADHD should ask their assigned provider about the specific diagnostic steps used before any controlled substance prescription.

Patient Satisfaction: What Customers Report

Consumer review aggregators show a polarized picture. Cerebral carries approximately 3.2 out of 5 stars on Trustpilot based on over 4,000 reviews, with the most common complaints centering on three areas: difficulty reaching customer support, provider turnover mid-treatment, and billing confusion after cancellation.

Positive reviews consistently mention convenience, fast initial appointments (often within 48 hours), and effective medication management once a stable provider relationship is established. Negative reviews cluster around discontinuity of care. Multiple reviewers describe being reassigned to new prescribers two or three times within a six-month span.

Provider continuity matters clinically. A 2022 study in The BMJ (N=26,354 primary care patients) found that patients seeing the same physician for 80%+ of visits had 22% fewer emergency department presentations compared to those with low continuity (adjusted IRR: 0.78 to 95% CI: 0.71 to 0.85) [11]. While this data comes from primary care rather than psychiatry, the principle applies: therapeutic relationships take time to build, and frequent provider changes may undermine treatment adherence.

Billing transparency is another friction point. Several state attorneys general have received complaints about Cerebral's auto-renewal practices and the difficulty of obtaining refunds after cancellation. Patients should verify cancellation terms in writing before subscribing, and should confirm whether their insurance plan is actively contracted with Cerebral or merely billed out-of-network at a higher patient cost.

Cerebral vs. Alternatives: How Does It Compare?

The telehealth mental health market includes several direct competitors: Done, Talkiatry, Brightside Health, and Alma among them. Each operates differently.

Talkiatry distinguishes itself by employing psychiatrists directly (not nurse practitioners) and billing insurance as in-network for most major plans. A 2023 analysis of Medicare claims data found that psychiatrist-led telehealth visits resulted in slightly lower 30-day readmission rates compared to NP-led visits (3.1% vs. 4.7%, p=0.02), though baseline severity may confound this comparison [12].

Brightside Health has published its own outcomes data, reporting that 86% of members with moderate-to-severe depression (baseline PHQ-9 >10) achieved response or remission within 12 weeks [13]. This figure comes from an internal dataset and has not been independently replicated, but it establishes a benchmark that Cerebral has not publicly matched with its own published outcomes.

Done, like Cerebral, faced DEA scrutiny over stimulant prescribing. The company's co-founder was indicted in 2024 on federal charges related to unlawful distribution of Adderall [14]. This case is distinct from Cerebral's situation, but it illustrates the regulatory risk across the sector.

Alma operates as a provider network rather than a direct employer, connecting patients with independent therapists and psychiatrists who accept insurance. This model avoids many of the continuity complaints seen with Cerebral, since providers maintain their own panels.

Choosing between these platforms depends on three variables: whether your insurance is accepted, whether you need medication management or therapy or both, and whether you specifically need ADHD stimulant prescribing. For depression and anxiety medication management, the platforms produce broadly similar outcomes when prescribers follow guideline-concordant care [15].

What Medications Does Cerebral Prescribe?

Cerebral prescribers can write prescriptions for most non-controlled psychiatric medications and, with additional evaluation, select controlled substances. The most commonly prescribed medication classes include:

SSRIs and SNRIs for depression and anxiety: sertraline (Zoloft), escitalopram (Lexapro), fluoxetine (Prozac), venlafaxine (Effexor XR), and duloxetine (Cymbalta). These remain first-line treatments per the APA Practice Guidelines for Major Depressive Disorder, which recommend SSRIs as initial pharmacotherapy for moderate-to-severe depression [16].

Buspirone for generalized anxiety disorder. Non-habit-forming. Takes 2 to 4 weeks for full effect.

Hydroxyzine for acute anxiety. Works within 30 to 60 minutes. Not a controlled substance.

Stimulants for ADHD (after enhanced evaluation): methylphenidate (Ritalin, Concerta), mixed amphetamine salts (Adderall), and lisdexamfetamine (Vyvanse). These are Schedule II controlled substances subject to the platform's tightened diagnostic protocol.

Non-stimulant ADHD medications: atomoxetine (Strattera), guanfacine ER (Intuniv), and viloxazine (Qelbree). These do not require DEA scheduling and can be prescribed without the additional evaluation steps.

Bupropion (Wellbutrin) for depression, particularly in patients who experience SSRI-related sexual side effects or weight gain. Also used off-label for ADHD in adults who cannot tolerate stimulants.

Cerebral does not prescribe benzodiazepines (alprazolam, lorazepam, clonazepam) for new patients, a policy the company adopted in 2022. This restriction aligns with the APA's position that benzodiazepines should generally be second-line for anxiety disorders due to dependence risk [17].

Cost Breakdown and Insurance Coverage

Cerebral offers three primary plan tiers for patients paying out-of-pocket. Medication management only runs approximately $85 per month. Medication management plus therapy costs roughly $259 per month. Therapy only is priced at approximately $325 per month. These prices fluctuate by state and promotional offers.

For insured patients, copays depend on the specific plan. Cerebral is in-network with Cigna, Aetna, Anthem Blue Cross, Highmark, and select regional carriers. Patients with UnitedHealthcare, Kaiser, or Medicare may need to pay out-of-pocket or seek alternative platforms.

A cost comparison is informative. The national average cost of an in-person psychiatry visit ranges from $200 to $500 for a new patient evaluation and $100 to $300 for follow-ups, per the American Psychiatric Association's 2023 practice survey [18]. Cerebral's $85 per month medication management plan, which includes one monthly prescriber visit, falls below the national average per-visit cost for uninsured patients.

The catch: therapy-inclusive plans at $259 to $325 per month exceed what many patients pay through insurance for in-network outpatient therapy, where copays often range from $20 to $50 per session. Patients with good insurance coverage for outpatient mental health may find better value using a traditional provider or a platform like Talkiatry that bills insurance directly for psychiatric visits.

Is Cerebral Legitimate? Regulatory Standing and Licensing

Cerebral is a legitimate, licensed healthcare company. It operates under state-by-state medical practice regulations, employs or contracts with licensed psychiatric nurse practitioners, physician assistants, and physicians, and holds the necessary state telehealth licenses to practice in all 50 U.S. states plus Washington, D.C. [19].

The DOJ investigation raised questions about prescribing practices, not about the company's licensure or the legitimacy of its medical services. No charges have been filed against Cerebral as a corporate entity as of early 2026. The investigation focused on the adequacy of evaluation procedures before prescribing controlled substances, a clinical quality concern rather than a fraud allegation.

Cerebral is HIPAA-compliant and uses encrypted video conferencing for all patient encounters. The company's privacy practices came under separate scrutiny in 2023 when it disclosed that it had shared certain patient data with advertising platforms through website tracking pixels, a practice that affected several telehealth companies including BetterHelp [20]. Cerebral self-reported this issue to the HHS Office for Civil Rights and agreed to implement corrective measures.

For patients evaluating whether Cerebral is "legit," the answer is yes, with caveats. The platform provides licensed medical care. Its prescribers hold valid credentials. Its regulatory history, however, warrants attention, particularly for patients seeking ADHD treatment with controlled substances. Ask your assigned provider for their credentials, their diagnostic process, and their approach to monitoring treatment response over time.

Patients with complex psychiatric histories, including prior hospitalizations, active suicidal ideation, or psychotic features, should seek in-person care. Cerebral's own intake screening excludes patients reporting active suicidal intent, directing them to the 988 Suicide & Crisis Lifeline or emergency services [21].